€
1. 03
0
0%
€
56.6M Market Cap
- P/E Ratio
- Div Yield
500 Volume
- Eps
€ 1.03
Previous Close Want to track L6J and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
L6J trading today higher at €1.03, an increase of 0% from yesterday's close, completing a monthly decrease of -44.1432% or -€0.81. Over the past 12 months, L6J stock lost -58.2996%.
L6J is not paying dividends to its shareholders.
The last earnings report, released on Mar 06, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 4 different exchanges and in various currencies, with the primary listing on XFRA (EUR).
Aiforia Technologies Oyj (L6J) FAQ
What is the stock price today?
The current price is €1.03.
On which exchange is it traded?
Aiforia Technologies Oyj is listed on XFRA.
What is its stock symbol?
The ticker symbol is L6J.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 56.6M.
Has Aiforia Technologies Oyj ever had a stock split?
No, there has never been a stock split.
Aiforia Technologies Oyj Profile
| Health Care Technology Industry | Healthcare Sector | Mr. Jukka Tapaninen M.Sc(Econ) CEO | XFRA Exchange | FI4000507934 ISIN |
| DE Country | 76 Employees | - Last Dividend | - Last Split | - IPO Date |
Aiforia Technologies Oyj, together with its subsidiary, Aiforia Inc., provides AI-based image analysis software used in clinical, preclinical, and academic laboratories to pathologists and researchers in Finland, rest of Europe, North America, and internationally. It offers tools for AI-supported diagnostics and visualization of patient samples, as well as automated screening and reporting tools for the treatment of various cancers, such as breast, lung, and prostate cancer; CE-IVD marked Aiforia clinical suite viewer for the clinical pathology workflow; and Aiforia Create, an agile solution to develop an AI model for image analysis application. The company's products are used for the treatment of Parkinson's disease, organ transplantation, and liver and inflammatory bowel diseases. It serves academic institutes and pharmaceutical companies through direct and sales partners. The company was incorporated in 2013 and is headquartered in Helsinki, Finland.
Contact Information
Address: Pursimiehenkatu 29-31 D 610, Helsinki, Finland, 00150
Phone: 358 2073 49130
Website: https://www.aiforia.com
